Myosin 15 Promoters and Uses Thereof
Summary
The European Patent Office published patent application EP3784289A1 for Decibel Therapeutics' Myosin 15 promoters and their therapeutic uses in hearing loss treatment. The application covers gene therapy compositions targeting myosin 15 expression for the treatment of hearing disorders. The patent is designated across 35 European member states including DE, FR, GB, IT, ES, NL, and others.
What changed
EPO published patent application EP3784289A1 (Publication A1) filed by Decibel Therapeutics, Inc. covering Myosin 15 promoters and their uses for hearing loss therapy. The application includes IPC classifications A61K 48/00 (gene therapy) and C12Q 1/6883/6897 (diagnostic methods for hearing loss). The designated states cover all 35 EPO member states and extension countries.
This patent publication provides public notice of Decibel Therapeutics' intellectual property claims in the hearing loss gene therapy space. Competitors developing myosin 15-related therapeutics or diagnostics should review the published claims to assess freedom-to-operate implications. No compliance actions or deadlines apply to this publication.
Source document (simplified)
MYOSIN 15 PROMOTERS AND USES THEREOF
Publication EP3784289A1 Kind: A1 Mar 25, 2026
Applicants
Decibel Therapeutics, Inc.
Inventors
BURNS, Joseph, ELLIS, Kathryn, PALERMO, Adam, SCHWANDER, Martin, WHITTON, Jonathon
IPC Classifications
A61K 48/00 20060101AFI20211208BHEP C12Q 1/6883 20180101ALI20211208BHEP C12Q 1/6897 20180101ALI20211208BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.